Latest Risk Factors News

WhiteHawk Limited is offering 139.3 million WHKOB Options to placement participants and its lead manager, exercisable at $0.013 and expiring in 2029. The options are issued for nil consideration, with potential proceeds of $1.81 million if fully exercised.

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for its suite of 27 ETFs on the ASX, updating investment strategies, fee structures, risk factors, and operational details.

Stavely Minerals has completed all key technical work for its Thursday’s Gossan and Cayley Lode Scoping Study, but the final report release has been postponed to late July due to personal circumstances affecting the lead author.

Hawk Resources has launched an options offer following a $3 million placement, aiming to fund exploration at its scandium and copper projects in Australia and the US.

Tennant Minerals (ASX:TMS) has launched a prospectus offering more than 800 million new options, aiming to clear trading restrictions and raise funds for advancing its Bluebird project and broader exploration activities.

Titanium Sands Limited (ASX:TSL) has launched a fully underwritten offer of up to 242.7 million New Options to holders of its expired TSLOA Options, aiming to raise approximately $243,000 before expenses. The offer includes a substantial bonus component and options allocated to CPS Capital as fees for managing a $1.2 million loan.

Sabre Resources (ASX:SBR) has lodged a prospectus offering up to 530 million new options, aiming to clear trading restrictions and raise capital for exploration and acquisitions.

American Tungsten & Antimony Ltd has inked an underwriting deal with GBA Capital to ensure full subscription of up to 69 million AT4N options expiring this month, securing potential capital injection amid its US critical minerals push.

Centuria Capital Group has launched the retail component of its $100 million entitlement offer, aiming to raise approximately $35 million. The equity raising supports expansion in AI infrastructure and real estate funds management.

SunRice reported a 4% rise in net profit after tax for FY26 to $73.3 million, maintaining an 8% EBITDA margin despite a 2.5% revenue decline. The company declared a record fully franked dividend of 70 cents per share but expects FY27 profit to fall amid a smaller Australian rice crop.

Buru Energy has launched a prospectus offering over 207 million new options free-attaching to a recent $5.3 million placement, aiming to back the commercialisation of its Rafael Gas Project and bolster working capital.

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.